Avoid common mistakes on your manuscript.
Dear Editor,
We agree with Drs. Shekar and Fraser about the importance of studying the effect of extracorporeal circuitry on the pharmacokinetics of medications commonly used in critically ill patients receiving extracorporeal membrane oxygenation (ECMO). The great majority of such studies currently in the literature were conducted in neonates or with outdated extracorporeal technology. It is problematic to apply the results of these studies to adults on ECMO contemporaneously because of physiological differences between the populations and the recent advances in ECMO circuit materials. The studies proposed by the authors could have far-reaching impact on the management of patients receiving ECMO, and we look forward to the results of their ongoing research.
Conflicts of interest
Dr. Brodie reports receiving research support from Maquet Cardiovascular, including travel expenses for research meetings, research support for the present study as well as anticipated support for upcoming studies and compensation paid to Columbia University for research consulting. He receives no direct compensation from Maquet. Dr. Brodie is a member of the Medical Advisory Board for ALung Technologies. Compensation is paid to Columbia University. Dr. Brodie receives no direct compensation from ALung Technologies. Pr. Combes is the primary investigator of the EOLIA trial, NCT01470703, a randomized trial of VV-ECMO supported in part by MAQUET. Pr. Combes has received honoraria for lectures by MAQUET.
Author information
Authors and Affiliations
Corresponding author
Additional information
This reply refers to the comment available at: doi:10.1007/s00134-013-3080-z.
Rights and permissions
About this article
Cite this article
Abrams, D., Brodie, D. & Combes, A. Correspondence to: can optimal drug dosing during ECMO improve outcomes?. Intensive Care Med 39, 2238 (2013). https://doi.org/10.1007/s00134-013-3084-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-013-3084-8